Biotech start-up Cue Health has received a $13 million contract from the U.S. Department of Health and the Human Services Advanced Biomedical Research and Development Agency (BARDA),media reported. The work will be used to speed up the development and testing of handheld molecular tests that can detect THE SARS-CoV-2 new coronavirus that causes new coronary pneumonia.
Cue is understood to be developing a product that pairs the cartridge test kit with a compact, networked mini-lab device. Mini Lab devices deliver results to an app-based personalized health dashboard.
In fact, the start-up received a $30 million contract from BARDA as early as 2018 to develop and validate an over-the-counter diagnostic test for influenza and multiple respiratory pathogens. The company said the pre-existing relationship and work would help launch the development of the new coronal pneumonia test. In the same year, the company also raised $45 million in round B funds.
“Over the past two years, we have worked with the BARDA team to develop and test a 20-minute molecular influenza test designed for home and care use,” Cue Health CEO Ayub Khattack said in a statement. Our networked platform can be a key tool for identifying SARS-CoV-2 viruses. “
Cue’s proposed test solution uses samples taken from nasal swabs to deliver results in less than 25 minutes, and all tests are completed on site without any round-trip transportation.